A Phase 1 interventional study of Bomedemstat in Hepatic Insufficiency, sponsored by Merck Sharp & Dohme LLC. Completed at 3 sites in United States. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-02-25.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies in Hepatic Insufficiency by Merck & Co., Inc — 1 open to participants now, 1 under way, none of them phase 3. Hepatic Insufficiency · Merck & Co., Inc.
Among the 10 studies in Hepatic Insufficiency by Merck & Co., Inc, this one is the 9th largest by enrollment, is the only one that started in 2025, is one of 10 in phase 1, and was the 10th registered.
113 studies on the registry are indexed under Hepatic Insufficiency; 15 are open to participants now.
Browse Hepatic Insufficiency studies →1 of the 10 studies in Hepatic Insufficiency by Merck & Co., Inc is open now. Recruiting first, the newest first:
Merck Sharp & Dohme LLC
Ages 18–75 · Healthy volunteers
Of the 9 Hepatic Insufficiency studies recruiting now, 3 set no upper age limit and 3 stop at 75 or younger; 1 takes children under 18; 4 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 1 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 9 is below the median of 29 across 100 interventional studies indexed under Hepatic Insufficiency.
Median enrollment 20 across the 10 interventional studies. Of the 9 that completed or were terminated, 5 (56%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Merck Sharp & Dohme LLC, one of the names counted as Merck & Co., Inc. Under that name alone:
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
1 of the studies in Hepatic Insufficiency by Merck & Co., Inc that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05093972Merck Sharp & Dohme LLCUlonivirine (MK-8507) in Participants With Mild or Moderate Hepatic Impairment (MK-8507-014) | 2027-06-29 |
Add it to your calendar (.ics) → With an account.
Among the 10 studies in Hepatic Insufficiency by Merck & Co., Inc, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to learn what happens to bomedemstat (MK-3543) in a person's body over time. Researchers will compare what happens to bomedemstat in the body when it is given to participants with mild or moderate hepatic (liver) impairment and healthy participants.
Participants will be allocated to one of three groups: mild hepatic impairment (HI), moderate HI, or healthy matched control. All participants will receive a single oral dose of bomedemstat on Day 1.
Healthy control participants will be enrolled after hepatic impairment participants have been dosed. Healthy control participants will be matched for the mean age and mean body-mass index (BMI) of all participants with HI (mild and moderate HI combined) and sex to each HI group separately.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
The main inclusion criteria include but are not limited to the following:
Participants with Mild and Moderate HI
Healthy Control Participants:
Exclusion Criteria
The main exclusion criteria include but are not limited to the following:
All Participants
Participants with Mild and Moderate HI
Healthy Control Participants
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants with mild hepatic impairment will receive a single oral 25 mg dose of bomedemstat on Day 1.
Drug: Bomedemstat
Participants with mild hepatic impairment will receive a single oral 25 mg dose of bomedemstat on Day 1.
Drug: Bomedemstat
Healthy participants will receive a single oral 25 mg dose of bomedemstat on Day 1.
Drug: Bomedemstat
Capsule for oral administration
Also known as: MK-3543
Area Under the Concentration-Time Curve from Time 0 to Infinity (AUC0-Inf) of Bomedemstat in Participants with Mild Hepatic Impairment (HI)
Blood samples collected to determine the AUC0-inf of bomedemstat.
Time frame: Up to 216 hours
Maximum Plasma Concentration (Cmax) of Bomedemstat in Participants with Mild HI
Blood samples collected to determine the Cmax of bomedemstat.
Time frame: Up to 216 hours
AUC0-Inf of Bomedemstat in Participants with Moderate HI
Blood samples collected to determine the AUC0-inf of bomedemstat.
Time frame: Up to 216 hours
Cmax of Bomedemstat in Participants with Moderate HI
Blood samples collected to determine the Cmax of bomedemstat.
Time frame: Up to 216 hours
Number of Participants Who Experience an Adverse Event (AE)
An AE is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants experiencing AEs will be reported.
Time frame: Up to 14 days
Number of Participants Who Discontinue Study Due to an AE
An AE is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants discontinuing study treatment due to an AE will be reported.
Time frame: Up to 14 days
Area Under the Concentration-Time Curve from Time 0 to Last (AUC0-Last) of Bomedemstat in Participants with Mild HI
Blood samples will be collected to determine the AUC0-last of bomedemstat.
Time frame: Up to 216 hours
Area Under the Concentration-Time Curve from Time 0 to 24 hours (AUC0-24hrs) of Bomedemstat in Participants with Mild HI
Blood samples will be collected to determine the AUC0-24hr of bomedemstat.
Time frame: At designated timepoints up to 24 hours postdose
Plasma Concentration at 24 Hours (C24) of Bomedemstat in Participants with Mild HI
Blood samples will be collected to determine the C24 of bomedemstat.
Time frame: At designated timepoints up to 24 hours postdose
Time to Maximum Plasma Concentration (Tmax) of Bomedemstat in Participants with Mild HI
Blood samples will be collected to determine the Tmax of bomedemstat.
Time frame: Up to 216 hours
Apparent Terminal Half-life (t1/2) of Bomedemstat in Participants with Mild HI
Blood samples will be collected to determine the t1/2 of bomedemstat.
Time frame: Up to 216 hours
Apparent Clearance (CL/F) of Bomedemstat in Participants with Mild HI
Blood samples will be collected to determine the CL/F of bomedemstat.
Time frame: Up to 216 hours
Apparent Volume of Distribution During Terminal Phase (Vz/F) of Bomedemstat in Participants with Mild HI
Blood samples will be collected to determine the Vz/F of bomedemstat.
Time frame: Up to 216 hours
AUC0-Last of Bomedemstat in Participants with Moderate HI
Blood samples will be collected to determine the AUC0-last of bomedemstat.
Time frame: Up to 216 hours
AUC0-24hrs of Bomedemstat in Participants with Moderate HI
Blood samples will be collected to determine the AUC0-24hr of bomedemstat.
Time frame: At designated timepoints up to 24 hours postdose
C24 of Bomedemstat in Participants with Moderate HI
Blood samples will be collected to determine the C24 of bomedemstat.
Time frame: At designated timepoints up to 24 hours postdose
Tmax of Bomedemstat in Participants with Moderate HI
Blood samples will be collected to determine the Tmax of bomedemstat.
Time frame: Up to 216 hours
t1/2 of Bomedemstat in Participants with Moderate HI
Blood samples will be collected to determine the t1/2 of bomedemstat.
Time frame: Up to 216 hours
CL/F of Bomedemstat in Participants with Moderate HI
Blood samples will be collected to determine the CL/F of bomedemstat.
Time frame: Up to 216 hours
Vz/F of Bomedemstat in Participants with Moderate HI
Blood samples will be collected to determine the Vz/F of bomedemstat.
Time frame: Up to 216 hours
Plan to share: Yes — https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf
Data sharing details ↗ · externaldatasharing-msd.com
Ran from Aug 2025 to primary completion in Feb 2026, 5 months.
Of 38 industry-sponsored phase 1 interventional studies under Hepatic Insufficiency, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 17. This study's 5 months is below that.
Counting every sponsor, half of 41 studies reached it within 8 months; a quarter within 5 and three quarters within 17.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Bomedemstat